Altria Group: Focus on Oral Tobacco Products and Growth

Dec.01.2022
Altria Group: Focus on Oral Tobacco Products and Growth
Altria Group's focus on oral tobacco products leads to expected growth in adjusted earnings per share by 4.5-6%.

US tobacco company Altria Group, Inc. (MO) appears well-prepared to tackle rising costs and weak cigarette sales by focusing on oral tobacco products, thanks to its strong pricing power. The company is expecting adjusted earnings per share between $4.81 and $4.89 in 2022, a growth of 4.5-6% compared to $4.61 in 2021.


Let's delve deeper and take a closer look.


Factors supporting Altria


Due to the serious health risks associated with smoking, consumers are turning to products with reduced risk or no smoke. Altria has been adapting to the changing market by offering a variety of oral, electronic, and heated tobacco products. Altria, through its subsidiary Helix Innovations, owns on!, a popular tobacco-derived nicotine (TDN) pouch product. Management believes that on! is worth mentioning as part of Altria's smoke-free product portfolio as oral TDN products are becoming more popular in the US due to their low-risk claims. In the third quarter of 2022, the net revenue of the oral tobacco products segment increased by 7% compared to the same period last year to $665 million due to price increases. The domestic shipment volume of this segment increased by 1.3%, mainly due to changes in trade inventory, industry growth rate, and calendar differences, with reported shipping volume soaring by about 70%. Additionally, the retail market share of oral tobacco increased compared to the previous quarter, reaching 5.2 share points in the third quarter.


Altria Group surprises with price, consensus, and earnings per share.


Tobacco giant Altria has remained strong thanks to its powerful pricing ability, even during periods of weak cigarette shipments and increased taxes. While higher prices may lead to decreased cigarette consumption, it appears that due to the addictive nature of cigarettes, smokers are willing to accept price hikes. In Q3 of 2022, higher pricing supported revenue in Altria's smokeable and oral tobacco product segments. Additionally, higher pricing helped the adjusted operating company income for both segments. This trend may continue to have room for growth.


Barrier or obstacle.


Cost inflation and rising natural gas prices were unfavorable factors in the third quarter. Additionally, wage costs increased. The continued presence of these factors remains a concern. Management's outlook for 2022 takes into account planned investments related to costs aimed at improving the digital consumer engagement system, strengthening research, development, and regulatory readiness costs for smokeless products, and supporting marketing activities for the company's smokeless products. The outlook also includes expectations for inflation in settlement agreement costs, as well as direct and indirect material costs. In the third quarter of 2022, Altria's net income decreased by 3.5% year-on-year to $6.55 billion, due to lower revenue from the wine segment divestment in October 2021 and decreased revenue from the combustible products segment. Excluding excise taxes, revenue decreased by 2.2% to $5.412 billion.


In the field of smoking products, net income decreased by 1.6% year-on-year to $5.882 billion due to decreased shipments and increased promotional investments. Domestic cigarette shipments fell by 9.2% year-on-year, primarily driven by industry decline and losses in retail market share. However, changes in trade inventory partially offset this impact. After adjusting for changes in trade inventory and other factors, estimates indicate that domestic cigarette shipments for smoking products decreased by 8%.


Bottom line


Overall, cigarette sales have been impacted by increased consumer health awareness and regulatory barriers. However, according to a third quarter earnings call with management, research suggests that despite price increases in the tobacco category compared to other categories, tobacco consumers are more likely to continue purchasing their preferred brands. Pricing power and advantages with smokeless tobacco products may keep Altria on a growth trajectory. The stock price of this third-ranked (hold) Zacks company has risen 1.5% over the past three months, compared to the industry's 1% increase.


2FIRSTS will continue to cover this topic, with updates available on the "2FIRSTS APP". Scan the QR code below to download the app.


This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai
Product | SKE Launches Disposable V-BOT, Claiming U.S. Manufacturing and Domestic Blending & Filling
Product | SKE Launches Disposable V-BOT, Claiming U.S. Manufacturing and Domestic Blending & Filling
SKE has launched the V-BOT disposable e-cigarette. The company’s website highlights that the device is “Made in the USA,” with blending and filling also completed domestically. The V-BOT features dual power modes (Eco/Boost), an 800 mAh rechargeable battery, and is advertised as delivering up to 40,000 puffs.
Nov.07 by 2FIRSTS.ai
69% of Russians Support Full Ban on E-Cigarette Sales, SuperJob Survey Shows
69% of Russians Support Full Ban on E-Cigarette Sales, SuperJob Survey Shows
According to Gazeta.Ru, a SuperJob poll found that 69% of Russians support President Vladimir Putin’s decision to fully ban vape sales in Russia. Only 7% oppose the ban, while 15% said they are indifferent and 9% were undecided.
Nov.10 by 2FIRSTS.ai
UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales
UK Experts Raise Concerns Over High-Dose Nicotine Pouches Amid Rising Sales
According to The Guardian, health experts in the UK are warning about the potential health effects of high-dose nicotine pouches as their sales continue to rise. Recent studies show teenagers reporting nicotine rushes, sickness and fainting, while researchers say packaging and marketing increasingly appeal to younger age groups. Although viewed as less harmful than cigarettes, experts remain concerned about their use among non-smokers, especially adolescents.
Nov.13 by 2FIRSTS.ai
RLX Technology Inc. (NYSE: RLX) Q3 2025 Financial Results: Net Revenue US$158.6 Million; International Business Accounts for 72%
RLX Technology Inc. (NYSE: RLX) Q3 2025 Financial Results: Net Revenue US$158.6 Million; International Business Accounts for 72%
RLX Technology Inc. (NYSE: RLX) announced its unaudited financial results for the third quarter of 2025. The company reported net revenue of RMB 1.13 billion, up 49.3% year-on-year, and adjusted net profit of RMB 295.4 million, up 1.4% quarter-on-quarter. International business contributed 72% of total revenue, reflecting robust financial performance and continued shareholder returns.
Nov.14
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
EU to Abstain from WHO Tobacco Treaty Vote Amid Deep Internal Split
The European Union will abstain from voting at the upcoming 11th session of the WHO Framework Convention on Tobacco Control (COP11) in Geneva, following months of internal disagreement over how to regulate tobacco and nicotine products. The decision marks a rare and public fracture in EU health policy, reportedly driven by the European Commission’s hardline anti-tobacco stance.
Nov.18 by 2FIRSTS.ai